The combination of antitumor drugs, exemestane and erlotinib, induced resistance mechanism in H358 and A549 non-small cell lung cancer (NSCLC) cell lines

References

• Ben Sahra I, Laurent K, Giuliano S, et al. (2010). Targeting cancer cell metabolism: The combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 70:2465–75
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL, Manson JE, et al. (2010). Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. J Natl Cancer Inst 102:1413–21
   PubMed Web of Science ®Google Scholar
• Feld R, Sridhar SS, Shepherd FA, et al. (2006). Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: A systematic review. J Thorac Oncol 1:367–76
   PubMed Web of Science ®Google Scholar
• Fischel JL, Formento P, Milano G. (2005). Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors. Br J Cancer 92:1063--8
   Google Scholar
• Garon EB, Pietras RJ, Finn RS, et al. (2013). Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J Thorac Oncol 8:270–8
   Google Scholar
• Giannopoulou E, Antonacopoulou A, Floratou K, et al. (2009a). Dual targeting of EGFR and HER-2 in colon cancer cell lines. Cancer Chemother Pharmacol 63:973–81
   PubMed Web of Science ®Google Scholar
• Giannopoulou E, Antonacopoulou A, Matsouka P, Kalofonos HP. (2009b). Autophagy: Novel action of panitumumab in colon cancer. Anticancer Res 29:5077–82
   PubMed Web of Science ®Google Scholar
• Hede K. (2007). Lung cancer may be different for men and women, but researchers ponder what to do? J Natl Cancer Inst 99:1830–2.
   Google Scholar
• Johnston SR. (2009). Enhancing the efficacy of hormonal agents with selected targeted agents. Clin Breast Cancer 9 Suppl 1:S28–36
   Google Scholar
• Koutras A, Giannopoulou E, Kritikou I, et al. (2009). Antiproliferative effect of exemestane in lung cancer cells. Mol Cancer 8:109
   Google Scholar
• Kuwada SK, Scaife CL, Kuang J, et al. (2004). Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells. Int J Cancer 109:291–301
   PubMed Web of Science ®Google Scholar
• Lefranc F, Facchini V, Kiss R. (2007). Proautophagic drugs: A novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist 12:1395–403
   PubMed Web of Science ®Google Scholar
• Lin SY, Makino K, Xia W, et al. (2001). Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nature Cell Biol 3:802–8
   PubMed Web of Science ®Google Scholar
• Mase K, Iijima T, Nakamura N, et al. (2002). Intrabronchial orthotopic propagation of human lung adenocarcinoma – Characterizations of tumorigenicity, invasion and metastasis. Lung Cancer 36:271–6
   Google Scholar
• Meng XN, Jin Y, Yu Y, et al. (2009). Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Br J Cancer 101:327–34
   PubMed Web of Science ®Google Scholar
• Niikawa H, Suzuki T, Miki Y, et al. (2008). Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res 14:4417–26
   PubMed Web of Science ®Google Scholar
• Osborne CK, Schiff R, Fuqua SA, Shou J. (2001). Estrogen receptor: Current understanding of its activation and modulation. Clin Cancer Res 7:4338s–42s; discussion 4411s–2s
   Google Scholar
• Pietras RJ, Marquez DC, Chen HW, et al. (2005). Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 70:372–81
   PubMed Web of Science ®Google Scholar
• Scaltriti M, Baselga J. (2006). The epidermal growth factor receptor pathway: A model for targeted therapy. Clin Cancer Res 12:5268–72
   PubMed Web of Science ®Google Scholar
• Siegfried JM, Hershberger PA, Stabile LP. (2009). Estrogen receptor signaling in lung cancer. Semin Oncol 36:524–31
   PubMed Web of Science ®Google Scholar
• Slatore CG, Chien JW, Au DH, et al. (2010). Lung cancer and hormone replacement therapy: Association in the vitamins and lifestyle study. J Clin Oncol 28:1540–6
   PubMed Web of Science ®Google Scholar
• Stabile LP, Lyker JS, Gubish CT, et al. (2005). Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 65:1459–70
   PubMed Web of Science ®Google Scholar
• Stabile LP, Siegfried JM. (2004). Estrogen receptor pathways in lung cancer. Curr Oncol Rep 6:259–67
   Google Scholar
• Takeuchi K, Ito F. (2010). EGF receptor in relation to tumor development: Molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors. FEBS J 277:316–26
   PubMed Web of Science ®Google Scholar
• Verma MK, Miki Y, Sasano H. (2011). Aromatase in human lung carcinoma. Steroids 76:759–64
   PubMed Web of Science ®Google Scholar
• Wang PH, Wang HC, Tsai CC. (2009). Estrogen replacement in female lung cancer during gefitinib therapy. Jpn J Clin Oncol 39:829–32
   Google Scholar
• Wang YC, Kulp SK, Wang D, et al. (2008). Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors. Cancer Res 68:2820–30
   PubMed Web of Science ®Google Scholar
• Weinberg OK, Marquez-Garban DC, Fishbein MC, et al. (2005). Aromatase inhibitors in human lung cancer therapy. Cancer Res 65:11287–91
   PubMed Web of Science ®Google Scholar
• Yoon YK, Kim HP, Han SW, et al. (2010). KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach. Mol Carcinog 49:353–62
   PubMed Web of Science ®Google Scholar
• Yue X, Song W, Zhang W, et al. (2008). Mitochondrially localized EGFR is subjected to autophagic regulation and implicated in cell survival. Autophagy 4:641–9
   PubMed Web of Science ®Google Scholar